TY - JOUR
T1 - Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin
T2 - A 1-year, double-blind, randomized clinical trial
AU - Derosa, Giuseppe
AU - D'Angelo, Angela
AU - Fogari, Elena
AU - Salvadeo, Sibilla
AU - Gravina, Alessia
AU - Ferrari, Ilaria
AU - Cicero, Arrigo F G
PY - 2007/11/16
Y1 - 2007/11/16
N2 - Objective: To evaluate the effect on coagulation and fibrinolysis parameters and on non-conventional cardiovascular risk factors of metformin plus nateglinide or glibenclamide in naive type 2 diabetes patients. Patients and Methods: A total of 248 type 2 diabetic patients were enrolled and randomly assigned to receive nateglinide or glibenclamide, and netformin for 12 months. We assessed body mass index (BNH), glycated hemoglobin (HbA17c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma-insulin (FPI), postprandial plasma insulin (PPI), homeostasis model assessment index (HOMA index), lipid profile with lipoprotein (a) [Lp(a)], fibrinogen (Fg), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (t-PA), homocysteine (Hcy), systolic blood pressure (SBP), diastolic blood pressure (DBP). Results: After 9 months of treatment, both tested drug combinations were similarly associated with a significant reduction in FPG (nateglinide, -17.2%; glibenclamide, -16.9%, both p1c (-17.3%, p1c (-21%, p1c, (41%, p1c, difference value from baseline observed in the nateglinide-treated group was significantly higher than that observed in the glibenclamide group. Therefore the nateglinide-treated patients showed a significant reduction in some prothrombotic parameters (PAI-1=49%, Lp(a)=-31%, and Hcy=-32.3%, all p
AB - Objective: To evaluate the effect on coagulation and fibrinolysis parameters and on non-conventional cardiovascular risk factors of metformin plus nateglinide or glibenclamide in naive type 2 diabetes patients. Patients and Methods: A total of 248 type 2 diabetic patients were enrolled and randomly assigned to receive nateglinide or glibenclamide, and netformin for 12 months. We assessed body mass index (BNH), glycated hemoglobin (HbA17c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma-insulin (FPI), postprandial plasma insulin (PPI), homeostasis model assessment index (HOMA index), lipid profile with lipoprotein (a) [Lp(a)], fibrinogen (Fg), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (t-PA), homocysteine (Hcy), systolic blood pressure (SBP), diastolic blood pressure (DBP). Results: After 9 months of treatment, both tested drug combinations were similarly associated with a significant reduction in FPG (nateglinide, -17.2%; glibenclamide, -16.9%, both p1c (-17.3%, p1c (-21%, p1c, (41%, p1c, difference value from baseline observed in the nateglinide-treated group was significantly higher than that observed in the glibenclamide group. Therefore the nateglinide-treated patients showed a significant reduction in some prothrombotic parameters (PAI-1=49%, Lp(a)=-31%, and Hcy=-32.3%, all p
KW - Glibenclamide
KW - Metformin
KW - Nateglinide
KW - Prothrombotic parameters
UR - http://www.scopus.com/inward/record.url?scp=36749099327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36749099327&partnerID=8YFLogxK
U2 - 10.2169/internalmedicine.46.0320
DO - 10.2169/internalmedicine.46.0320
M3 - Article
C2 - 18025765
AN - SCOPUS:36749099327
VL - 46
SP - 1837
EP - 1846
JO - Internal Medicine
JF - Internal Medicine
SN - 0918-2918
IS - 22
ER -